Biomoda, Inc. joins with France’s Majestic Sarl to enter Common Market

Outsourcing is extended to Rapidly gain approval in France for Cancer Detection and Treatment Products and Systems.

Albuquerque, N.M. –(Business Wire), July 14, 2004 - Biomoda, Inc. has completed negotiations with Majestic Sarl (Sociéte a responsabilité limité), based in Vaugrigneuse, France. D. Lescasse-Laurent, Managing Director of Majestic will provide personal supervision to support the evaluation of Biomoda’s cancer diagnostic products and systems. Majestic has agreed to file Biomoda’s application of a CE Mark in France. Upon approval by the Ministry of Health of France, and more specifically at  AFSSAPS (Agence Française de Sécurité Sanitaire de Produits de Santé), Biomoda’s patents and systems will be processed for other European markets. AFSSAPS combines approvals for both In Vivo and In Vitro products into the French market.

Majestic, and in particular Mme. Lescasse-Laurent provide medical product commercialization consultation and management assistance to many of the world’s leading bio-medical organizations.

Biomoda, Inc., a development stage in-vitro diagnostics organization, is focused on research, development and commercialization of cancer diagnostics. The Company, exclusive worldwide licensee from the University of California of several patents developed for noninvasive early detection and treatment of lung cancer is in the process of registering additional patents in this area.   The Company’s proprietary technologies provide minimally invasive and minimal impact approaches as cancer diagnostic products.  Operating from its laboratory situated at Kirtland Air Force Base (Albuquerque, NM), the Company is in the process of expanding and expediting its product development and commercialization with a number of strategic alliances that will be announced over the next sixty days.   

* * * * *

This news release contains forward-looking statements that involve a high degree of risk and uncertainty. Such statements include, but are not limited to, statements containing the words “believes,” “anticipates,” “expects,” “estimates,” and words of similar import. The Company’s actual results could differ materially from any forward-looking statements, which reflect management’s opinions only as of the date of this report, as a result of risks and uncertainties that exist in our operation, development efforts and business environment. The Company undertakes no obligation to revise or publicly release the results of any revisions to these forward-looking statements. You should carefully review the risk factors in other documents that the Company files from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q. For additional information, visit the Biomoda web site at www.biomoda.com or call us at 505-821-0875.